Response to: "Successful implementation of phototherapy guidelines during the COVID-19 pandemic"

Henry W. Lim
Steve R. Feldman
Abby S. Van Voorhees
Joel M. Gelfand

Follow this and additional works at: https://scholarlycommons.henryford.com/dermatology_articles
Response to: “Successful implementation of phototherapy guidelines during the COVID-19 pandemic”

To the Editor: In the early months of the COVID-19 pandemic, guidance on delivering phototherapy was published to ensure the safety of patients and staff.1 It was developed based on the collective experience of the authors who supervised active phototherapy centers in 4 institutions; the recommendations have been successfully implemented in those institutions.

In this issue of the Journal, Dragan et al2 demonstrated that following the guidance, phototherapy was safely delivered between July 1, 2020, and January 1, 2021, to 36 patients covering 440 appointments. While the number of patients was small, it is reassuring that implementing the recommendations in a phototherapy unit located in a safety-net hospital in New York City resulted in no surge of SARS-CoV-2 infection among their patients. However, we also note the concern of Dragan et al2 about barriers to access for home phototherapy. Therefore, we are conducting the Light Treatment Effectiveness (LITE, NCT03726489) study, a pragmatic trial of home vs office-based phototherapy for psoriasis in 1050 patients across the US stratified by skin type, to improve our understanding of the effectiveness of home phototherapy for psoriasis with the ultimate goal of making the delivery of phototherapy more patient-centered. We encourage dermatologists, particularly those who treat diverse skin types, to join this important initiative (www.thelitestudy.com).

With cases primarily caused by the SARS-CoV-2 variant still increasing, continued adherence to this practical guide is recommended.

Henry W. Lim, MD, a Steve R. Feldman, MD, b Abby S. Van Voorhees, MD, c and Joel M. Gelfand, MD, MSCE d

From the Department of Dermatology, Henry Ford Health, Detroit, Michigan, a the Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, b the Department of Dermatology, Eastern Virginia Medical School, Norfolk, Virginia, c and the Department of Dermatology and Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. d

Funding sources: None.

IRB approval status: Not applicable.

Reprints not available from the authors.

Correspondence to: Henry W. Lim, MD, Department of Dermatology, Henry Ford Health System, 3031 West Grand Blvd, Suite 800, Detroit, MI 48202.

E-mail: blim1@hfhs.org

Conflicts of interest
None disclosed.

REFERENCES

https://doi.org/10.1016/j.jaad.2021.08.003